Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview

Annovis Bio

07/08/2026 15:58

Annovis Bio Inc ANVS.N, ANVS.K is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 45 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Annovis Bio Inc is $10.00, about 437.6% above its last closing price of $1.86
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.38
-0.39
-0.63
Missed
-59.5
Dec. 31 2026
-0.30
-0.34
-0.39
Missed
-13.6
Sep. 30 2025
-0.37
-0.30
-0.37
Missed
-21.3​
Jun. 30 2025
-0.43
-0.40
-0.32
Beat
20.5
​​Mar. 31 2025
-0.44
-0.36
-0.32
Beat
10.2
Dec. 31 2024
-0.29
-0.33
-0.43
Missed
-30.1​
Sep. 30 2024
-0.54
-0.53
-0.97
Missed
-84.4
Jun. 30 2024
-0.69
-0.63
-0.32
Beat
49.2
This summary was machine generated August 7 at 14:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)